'We'll create a scientific powerhouse': Pfizer defends AstraZeneca takeover bid
Monday 12 May 2014
Pfizer has defended its campaign to snap up AstraZeneca in Britain’s biggest foreign takeover claiming the £63 billion deal would create a “scientific powerhouse”.
The US drugmaker also hit back at politicians’ claims that its statement on UK jobs was not "watertight" as bosses from the two companies prepare to be grilled in Parliament tomorrow and on Wednesday.
In its select committee submissions, Pfizer said of its pledge to keep a fifth of the combined company’s research and development workforce in the UK for five years that although "we had no obligation to make these [jobs] commitments we were willing to do so because we support the opportunity to strengthen the UK life sciences industry.
"We understand fully that they would be binding as a matter of English law."
There are fears that a takeover could see Pfizer axe thousands of jobs, and top scientists — including the provost of University College, London — have warned that medical research in the UK could be “nullified” by the deal.
But Pfizer’s president of research, Mikael Dolsten, who will be giving evidence before the science and Technology select committee on Wednesday, made the unusual move of writing a newspaper column on why the potential takeover “would benefit patients around the world and strengthen the UK’s life sciences industry”.
Writing in the Evening Standard, Dolsten, who joined Pfizer as part of its $68 billion (£40 billion) acquisition of Wyeth in 2009, wrote that as a result he can "speak from personal experience on this subject".
"[The Wyeth deal] provoked similar concerns about the impact of a big merger on scientific progress."
Dolsten claimed the US Viagra-maker has “great respect” for AstraZeneca and its heritage but a merged business would be “better placed to meet society’s demand for the faster and more cost-effective delivery of medicines”.
His attempt to woo Astra’s investors, UK politicians and this country’s scientific community comes despite no firm offer being on the table from Pfizer. AstraZeneca rejected its most recent approach.
Pfizer points out: "AstraZeneca faces difficult challenges [such as] looming patent expiries," in its select committee submissions, but does not mention its own patent cliff, with Pfizer blockbusters including cholesterol treatment Lipitor facing generic competition.
Ian Read, Pfizer’s chief executive, has recorded four videos aiming at winning support for the deal, which he claimed would be a "win win" for investors and science.
AstraZeneca chief Pascal Soriot told The Independent that AstraZeneca was healthier as an independent medicine maker: "We are creating and investing in new drugs which we believe will transform how we tackle diseases and change patients’ lives."
- 3 Russian girl takes her own life after parents find pornography on her computer
- 4 Ball pool for adults opens in London
- 5 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
Michelle Obama highlights harsh restrictions faced by Saudi women after meeting King Salman without wearing a headscarf
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Kim Kardashian on Bruce Jenner's 'story': 'We support him no matter what, and I think when the time is right, he'll talk'
Russian girl takes her own life after parents find pornography on her computer
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...
Competitive salary & benefits!: MBDA UK Ltd: MBDA UK LTD Indirect Procurement...